Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1977 Feb;53(616):75–77. doi: 10.1136/pgmj.53.616.75

Practolol-induced autoantibodies and their relation to oculo-cutaneous complications.

S J Jachuck, J Stephenson, T Bird, F S Jackson, F Clark
PMCID: PMC2496620  PMID: 141660

Abstract

Tissue auto-antibodies were investigated in fifty-one patients (twenty-five female, twenty-six male) receiving practolol for ischaemic heart disease or dysrhythmias and compared with those found in 204 patients (fifty-eight female, 146 male) with ischaemic heart disease who did not receive practolol. Antinuclear factor (ANF) was found in 24% female and 16% male patients receiving practolol, but only in 5% of female and 4% of male patients who were not taking practolol. Thyroid cytoplasmic antibody (TCA) was detected in 16% female and 20% of male patients receiving practolol, compared to 10% of females and 6% of males in the control group. The incidence of ANF and TCA was significantly higher (P less than 0-05) in patients receiving practolol compared to the control group. The occurrence of gastric parietal cell antibody (PCA) and smooth muscle antibody (SMA) was not associated with practolol therapy (odds ratio of 2-4 and 1-9 respectively). The incidence of skin and eye complications was found to be 10% and the female to male ratio of this complication was 4 : 1. The correlation between autoantibody production and oculo-cutaneous complications could not be established in such a small group but three of the patients with the complications were found to have PCA, although PCA was found not to be associated with practolol therapy. Four of the five patients with the complications did not have circulating ANF.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amos H. E., Brigden W. D., McKerron R. A. Untoward effects associated with practolol: demonstration of antibody binding to epithelial tissue. Br Med J. 1975 Mar 15;1(5958):598–600. doi: 10.1136/bmj.1.5958.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bastenie P. A., Vanhaelst L., Bonnyns M., Neve P., Staquet M. Preclinical hypothyroidism: a risk factor for coronary heart-disease. Lancet. 1971 Jan 30;1(7692):203–204. doi: 10.1016/s0140-6736(71)90947-0. [DOI] [PubMed] [Google Scholar]
  3. Cumberbatch J. B. Letter: Skin reactions to beta-blockers. Br Med J. 1974 Nov 30;4(5943):528–528. doi: 10.1136/bmj.4.5943.528-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Farr M. J., Wingate J. P., Shaw J. N. Practolol and the nephrotic syndrome. Br Med J. 1975 Apr 12;2(5962):68–69. doi: 10.1136/bmj.2.5962.68-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holt P. J., Waddington E. Oculocutaneous reaction to oxprenolol. Br Med J. 1975 Jun 7;2(5970):539–540. doi: 10.1136/bmj.2.5970.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jachuck S. J., Husaini M. H. Intravenous practolol. Br Med J. 1971 Oct 30;4(5782):298–298. doi: 10.1136/bmj.4.5782.298-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jachuck S. J. Implanted-pacemaker-induced dysrhythmia and its management. Postgrad Med J. 1973 Jan;49(567):14–17. doi: 10.1136/pgmj.49.567.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jewitt D. E., Burgess P. A., Shillingford J. P. The circulatory effects of practolol (ICI 50172) in patients with acute myocardial infarction. Cardiovasc Res. 1970 Apr;4(2):188–193. doi: 10.1093/cvr/4.2.188. [DOI] [PubMed] [Google Scholar]
  10. Jewitt D. E., Mercer C. J., Shillingford J. P. Practolol in the treatment of cardiac dysrhythmias due to acute myocardial infarction. Lancet. 1969 Aug 2;2(7614):227–230. doi: 10.1016/s0140-6736(69)90001-4. [DOI] [PubMed] [Google Scholar]
  11. Mathews J. D., Whittingham S., Hooper B. M., Mackay I. R., Stenhouse N. S. Association of autoantibodies with smoking, cardiovascular morbidity, and death in the Busselton population. Lancet. 1973 Oct 6;2(7832):754–758. doi: 10.1016/s0140-6736(73)91037-4. [DOI] [PubMed] [Google Scholar]
  12. Max Sorsby L.M.S.S.A., M.R.C.G.P. Br Med J. 1975 Jun 28;2(5973):758–758. [PMC free article] [PubMed] [Google Scholar]
  13. Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973 May 26;2(5864):452–455. doi: 10.1136/bmj.2.5864.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Raftery E. B. Letter: cutaneous and ocular reactions to practolol. Br Med J. 1974 Dec 14;4(5945):653–653. doi: 10.1136/bmj.4.5945.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rowland M. G., Stevenson C. J. Exfoliative dermatitis and practolol. Lancet. 1972 May 20;1(7760):1130–1130. doi: 10.1016/s0140-6736(72)91482-1. [DOI] [PubMed] [Google Scholar]
  16. Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975 Mar 15;1(5958):595–598. doi: 10.1136/bmj.1.5958.595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES